| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dfab31402f484cf3b32ddfbc4bc1c5c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56961
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-14 |
| filingDate |
2016-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29fc17bed2a3c5ba3e8f175bdb6e7163
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e85d8378a3eb9e616760b5bc4de7b5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_676cbd5955329970885ea9cefcbbb30d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb30c4ef56aaaf1b1855c374de8ad462 |
| publicationDate |
2018-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3265485-A1 |
| titleOfInvention |
Antibody molecules and uses thereof |
| abstract |
This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines. |
| priorityDate |
2015-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |